SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway

SynAct Pharma AB ( (SE:SYNACT) ) has issued an update.

SynAct Pharma plans to raise about SEK 45 million via a directed share issue to Swedish and international qualified investors, with pricing set through an accelerated bookbuilding led by Navia Corporate Finance. Major shareholders such as Hunter Capital and Johannes Schildt, along with external investors, have signaled interest in participating, and the issue will deviate from existing shareholders’ preferential rights under a prior AGM mandate.

The company will use the proceeds to extend its financial runway and bolster flexibility ahead of key 2026 clinical readouts in rheumatoid arthritis and severe virus-induced hyperinflammation, positioning it for post-data partnering and strategic transactions. SynAct has also increased an undrawn shareholder credit facility from SEK 30 million to SEK 40 million and extended its maturity, reinforcing its balance sheet to reduce execution risk and strengthen negotiating leverage in future deal-making.

The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company developing resomelagon (AP1189), a first-in-class oral resolution therapy that stimulates the body’s natural ability to resolve inflammation rather than suppressing the immune system. Its lead Phase 2b ADVANCE trial targets newly diagnosed rheumatoid arthritis as a pre-biologic therapy, while additional Phase 2 programs in virus-induced hyperinflammation, including respiratory disease and dengue, broaden its potential market reach.

YTD Price Performance: -12.83%

Average Trading Volume: 137,443

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.05B

For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.